Daiichi Sankyo is a global research-driven pharmaceutical company headquartered in Tokyo, Japan. The company discovers, develops, manufactures, and markets prescription medicines, with operations spanning the Americas, Europe, and Asia.
Its core focus is oncology—particularly antibody-drug conjugates (ADCs) built on its DXd payload and linker platform—alongside cardiovascular and other therapeutic areas. Daiichi Sankyo maintains integrated R&D and GMP manufacturing capabilities covering small molecules, biologics, conjugation, and sterile fill‑finish, supported by quality, regulatory, and supply chain functions. The company collaborates with industry partners on targeted cancer therapies and supplies medicines worldwide. For the chemical and life sciences sector, Daiichi Sankyo is notable for its expertise in complex API synthesis, biologics production, and ADC process development, which combine medicinal chemistry, bioconjugation, and advanced manufacturing to deliver targeted therapeutics.
